Closing Ceremony

Is RDN Coming Back to Life?

Discussion

Which Is More Important, Morning BP or Nighttime BP?

Discussion

Significance and Problems of Primary Aldosteronism Screening in Hypertension Management?

Discussion

Do We Need a Global Guideline for Hypertension Management?

Discussion

Opening

Blood Pressure Management during COVID-19 Pandemic

Guideline-based SPC Treatment: From a Korean Perspective

The Clinical Benefits of SPC for Hypertensive Patients in China

Summary & Discussion

RAS System and Coronavirus Infections

Discussion

ACE2 in SARS-CoV-2: “Fuse” or “Fire extinguisher”?

Discussion

Will RAS Inhibitors Increase the Risk of SARS-CoV-2 Infection?

Discussion

Treatment of Hypertension Patients with COVID-19: Experience from Wuhan

Discussion

Hypertension Management during COVID-19 Pandemic: Opportunities and Challenges

Discussion

Remote BP Management during COVID-19 Pandemic: Advantage and Problem

Discussion

Internet Medicine in Management of Hypertension and Chronic Diseases during COVID-19 Pandemic

Discussion

Management of Blood Pressure Fluctuation during COVID-19 Pandemic

Discussion

Is Resistant Hypertension the Same as Refractory Hypertension?

Discussion

What Is True Resistant Hypertension

Discussion

Treatment Strategy of Resistant Hypertension in the Elderly

Discussion

Can Resistant Hypertension Be Cured?

Discussion

Prevention and Control of Hypertension in China: From the Global Perspective

Discussion

Hypertension and Sleep Apnea

Discussion

Natural Course and Cardiovascular Risk in Pre-Hypertension Population

Discussion

The Kailuan Cohort Study: Results of 15 Years

Discussion

Opening Speech

Application of Agalsidase-αfor Fabry Disease in Cardiology

Measurement to Optimize Overall Management of Hypertension

Closing

Role of Inflammation in Vascular Function in Hypertension

Discussion

Potential Therapeutic Targets for Improving Vascular Function in Hypertension

Discussion

Changes of Vascular Function and Structure from the Perspective of Time Dimension

Discussion

Progress on Vascular Function Testing

Discussion

1st Debate: Is Salt Sensitivity of Clinical Importance? : Pros

Discussion

1st Debate: Is Salt Sensitivity of Clinical Importance? : Cons

Discussion

2nd Debate: Should Reduced-Sodium Salt Be Popularized? : Pros

Discussion

2nd Debate: Should Reduced-Sodium Salt Be Popularized?: Cons

Discussion

Why Is It Hard to Have a Breakthrough in Basic Research of Hypertension?

The Molecular Mechanism of NPR3 in Hypertension

Epigenetics and Hypertension

Increased Lower Airway Resistance Is Involved in the Pathogenesis of OSA in Secondary Hypertension

The Advances in Mechanism and Evaluation of Vascular Aging

Complement Mediated Inflammatory Immunity and Vascular Aging

Worksite Hypertension Management: Evidence from China

Interpretation of Chinese Guideline for Diagnosis and Treatment of Hypertension in Primary Care

Community-Based Management of Hypertension: Patterns and Prospectives

Hypertension Control in Rural and Communities –Management and Popularization

Exploration of Hypertension Treatment Pattern in Primary Care

Recent Progress on Vascular Aging and Hypertension

Hypertension Management in Patients with Ischemic Stroke

Discussion

Risk Stratification and Management of Hypertension: What Should Primary Care Physicians Do?

Discussion

Hypertension with Multiple TOD: How to Determine the Target Blood Pressure?

Discussion

Hypertension Management in Patients with Hemorrhagic Stroke

Discussion

Measurement and Management of Family Blood Pressure in Primary Medical Institutions

Discussion

Ambulatory Blood Pressure Measurement and Diagnosis & Management of Hypertension

Discussion

Diagnosis and Treatment of Hypertensive Emergencies in Primary Care

Discussion

Screening for Secondary Hypertension in Primary Care: Clues and Considerations

Discussion

2019 Chinese Hypertension League Home Blood Pressure Monitoring Guideline

Discussion

Community-Based Management of Hypertension Complicated with Diabetes Mellitus

Community-Based Management of Hypertension Complicated with Heart Failure

Hypertension Complicated with Renal Disease

Management of Blood Lipid in Patients with Hypertension

Sleep Apnea and Hypertension

Characteristics and Management of Female Hypertensive Patients

2019 Chinese Guidelines on the Management of Hypertension in the Elderly

Discussion

Target Blood Pressure of Hypertension Management in the Elderly

Discussion

Management of Isolated Systolic Hypertension in the Elderly

Discussion

Characteristics of Hypertension in the Elderly

Discussion

Management of Postural Blood Pressure Changes in the Elderly

Discussion

Precautions in Selection of Antihypertensive Drugs for the Elderly

Discussion

Identification and Treatment of Adverse Reactions of Common Antihypertensive Drugs

Discussion

Medication Adherence and Influencing Factors of Antihypertensive Drug Use in Community

Discussion

Characteristics and Strategies of Drug Selection for Hypertension in Primary Care

Discussion

Value of Domestic Innovative Drugs in Community Hypertension

Discussion

Primary Care Physicians Is the Doorkeeper in Prevention and Management of Cardiovascular Disease

Discussion

Clinical Application of Comprehensive Risk Management Practice Guidelines on Cardiovascular Disease in Primary Care

Discussion

Guidelines on Diagnosis and Treatment of Dyslipidemia

Discussion

National Guidelines for Prevention and Control of Diabetes in Primary Care

Discussion

Prospect of Hypertension Management in the Era of Cloud Computing and Big Data

Discussion

“Internet Plus”and New Pattern of Community Hypertension Management

Discussion

Cognition Status of Internet Plus Medical Care in Hypertensive Patients

Discussion

Construction of Internet Platform for Antihypertensive Drug Consultation and Chronic Disease Management

Discussion

Current Status and Trend of Remote Blood Pressure Management in Community

Discussion

Application of Remote Hypertension Management in Rural Areas

Discussion

Precision Management of Blood Pressure in Community

Discussion

Construction of the National Standardized Hypertension Center in Primary Care

Discussion

The Basic Health Service Capacity Building in Primary Health Care

Future Development and Countermeasures of Hypertension Management in Community and Rural Areas

Training Strategy and Practice of Hypertension Management in Primary Care Physicians

Pattern of Hypertension Management in Kailuan

Community Family Doctors Should Implement Health Management and Prevent Complications of Hypertension

Hierarchical Medical Service in Ningbo

Conflicted ARR Criteria from the View of Testing Technique

Discussion

The Value of Genetics Diagnosis in Secondary Hypertension

Discussion

Dilemma of the Detection of Pheochromocytoma

Discussion

Diagnostic Role of Kidney Vein Blood Sampling in Reninoma

Discussion

The Effects of Gene Polymorphism on the Efficacy and Safety of Beta Blockers Treatment

1st Debate: Is the Dilemma of RDN from the Principle Itself or the Immature Technology? Pros: Principle Itself

Discussion

1st Debate: Is the Dilemma of RDN from the Principle Itself or the Immature Technology? Cons: Immature Technology

Discussion

2nd Debate: Is It Necessary to Apply Baroreflex Activation Therapy to Patients with Non-resistant Hypertension? Pros

Discussion

2nd Debate: Is It Necessary to Apply Baroreflex Activation Therapy to Patients with Non-resistant Hypertension? Cons

Discussion

Design and Implementation of Exercise Prescription for Patients with Hypertension

Discussion

Pharmaceutical and Non-Pharmaceutical Treatment for Weight Management in Patients with Hypertension

Discussion

Low Salt Diet: Practical Significance of Policy Guidance

Discussion

Sleep Management for Patients with Hypertension

Discussion

Optimal Antihypertensive Therapy for Hypertensives with Coronary Artery Disease

Optimal Antihypertensive Therapy for Acute Stroke Patients with Cardiovascular Disease

Adjustment of Antihypertensive Drugs in Patients with Hypertension and Renal Damage : From Proteinuria to Dialysis

Management of Hypertension with Atrial Fibrillation

Timing of Initiation of Low-Dose Triple Combination Therapy

How to Choose the Antihypertensive Drugs: A + C / A + D?

Mechanism of TMAO-Induced Perivascular Adipose Tissue in Hypertension

Research Progress on Mechanism of Salt Sensitive Hypertension

The Regulation Disorder of Renal Na+ Channels in Hypertension

HINT1 and Pressure Overload -Induced Hypertrophy

Sulfurous Gas Signal Molecule and Hypertension

Chlorine Ion and Hypertension

Pathogenesis and Intervention of Obesity-Related Hypertension

Discussion

Risk Assessment and Treatment Targets of Hypertensives with Hypercholesterolemia

Discussion

Treatments for Patients with Hypertension and Hyperuricemia

Discussion

Antihypertensive Effect and Cardiovascular Benefits of SGLT2i and GLP-1RA

Discussion

Video Display: Because I say so

Interpretation of Hotspots in ACC-ISH-ESC: A+ Protocol in Intensive Blood Pressure Treatment

A+ Protocol Is a Preferred Choice for Hypertensive Patients in China

Chinese Guidelines on Hypertension in 20 Years

Discussion

Global Impact of Recent US and European Hypertension Guidelines

Discussion

Interpretation of 2019 Japanese Hypertension Guidelines

Discussion

Interpretation of 2020 International Society of Hypertension (ISH) Global Guidelines

Discussion

Opening Speech

New Therapeutic Concept of Hypertension with Rapid Heart Rate

Interpretation of the Expert Consensus on the Management of Hypertension in the Young and Middle-Aged Chinese Population

Efficacy and Safety of Nitrendolol in the Treatment of Hypertension in Community

Long-Term Standardized Management of Hypertension

Discussion

Hypertension Management in Children and Adolescents

Hypertension Management in Young and Middle-aged Population

Management of Gestational Hypertension

Secondary Hypertension in Patients Susceptible to Target Organ Damage

Mechanism of Tumor-Targeted Therapies Induced Hypertension and Treatment

Management of Renal Hypertension

Evaluation and Management of Cardiac Injury Caused by Tumor Chemotherapy and Targeted Drugs

Discussion

Mechanism of by VEGF / VEGFR Pathway Inhibitors Induced Hypertension and Its Management

Discussion

Cardiac Toxicity in Targeted Therapy Drugs

Discussion

Clinical Cases of Targeted DrugsInduced Hypertension and Heart Failure

Discussion

Role of Vascular Stem/ Progenitor Cells in Arteriosclerosis

Discussion

Diet and Cholesterol Metabolism

Discussion

MiR-483-PCSK9 Pathway and Its Role in Atherosclerosis

Discussion

Gene Editing Therapy for Familial Hypercholesterolemia

Discussion

Research on the Relationship Between Small Molecule Gas Mediated Protein Modification and Cardiovascular Disease

Discussion

Current Status and Residual Risk of Lipid Lowering Therapy for Secondary Prevention of Atherosclerosis Cardiovascular Disease

Current Knowledge of Mechanism of Lp(A) on ASCVD

New Clinical Evidence of Lp(A) and ASCVD

Gene Therapy: a Novel Method of Lp(a) Targeted Therapy

Discussion: Are We Ready for the Era of LP (a) Targeted Therapy

Re-Discussion of Aspirin in Primary Prevention of Atherosclerotic Heart Disease

Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China

Role of Oral Anticoagulants in the Primary and Secondary Prevention of Coronary Artery Disease

Primary Prevention Strategy for Coronary Artery Disease in Patients with Familial Hypercholesterolemia

Current Cardiovascular Risk Stratification: View from China-PAR Project

Epidemiology and Current Status of Prevention and Treatment of Dyslipidemia Among Chinese Population

BVS: Progress and Considerations

Application of DCB in De-Novo Coronary Lesion

The Application of OCT in the Era of “Nothing Left”

“Nothing Left” – DCB: Data from Real-World

ADR: Experience from the Chinese Interventionalist

State-of-Art: CTO Interventional Therapy

What Can We Learn from the ISCHEMIA Study

Opening

ESC Spotlight: Focus on Lipid Management in AMI Patients

From Plaque Regression to Extremely High-risk Patient’s Intensive Lipid-lowering Therapy

PCSK9 Inhibitor Treatment in High-risk Patients with Complex Coronary Heart Disease

Role of PCSK9 Inhibitor’s in Individual Treatment for Dyslipidemia

Discussion

Progress on Antithrombotic Therapy after PCI

Discussion

Optimized Hypoglycemic Regimen for Patients with Coronary Artery Disease and Diabetes

Discussion

Antiplatelet Strategy for CAD Patients with Platelet Abnormalities after PCI

Discussion

SGLT2i and CAD: from Bench to Bedside

Discussion

From Successful PCI to the Treatment, the Integrated Optimized Lipid-lowering Strategy for ACS Patients

Discussion

Clinical Application of Platelet Function and Gene Testing

Lipoprotein (a) and Primary Prevention of Coronary Heart Disease

Discussion

Interpretation of Chinese Expert Consensus on the Management of Blood Lipids in Very-High-Risk ASCVD Patients

Discussion

Current Status and Prospects of Clinical Research on New Lipid-Lowering Target Lp(A)

Discussion

Interpretation of 2019 CCEP Expert Consensus on Lipid Management

Discussion

Perspective of Initial Combination Therapy from New Progress on Lipids-Lowering Studies

Interpretation of 2019 CCEP Chinese Experts Consensus

Developmental Progress of Novel Lipid-Regulating Drugs

Combined Lipid-Lowering Therapy, the General Trend

Discussion

Omega-3 Polyunsaturated Fatty Acids (Fish Oil) and Cardiovascular Disease Prevention

Management of Dyslipidemia with Triglyceride-rich Lipoprotein as the Target

Discussion

Interpretation of Expert Consensus on Antithrombotic Management of Patients with Atrial Fibrillation and Coronary Artery Disease

Discussion

PCSK9 Inhibitor and Acute Coronary Syndrome

Discussion

Clinical Characteristics and Prognostic Analysis of Patients with Coronary Artery Disease and Malignant Tumors

Discussion

Tumor Radio-Therapy and CAD

Discussion

The PCI Strategy for Patients with Coronary Artery Disease and Tumor

Discussion

Tumor Chemo-Therapy/Targeted Therapy and CAD

Discussion

Cancer Complicated with Coronary Artery Disease: View from an Oncologist

Discussion

Antithrombotic Management of Coronary Artery Disease Complicated with Atrial Fibrillation: Interpretation of 2020 Chinese Expert Consensus

Discussion

Antithrombotic Management of Atrial Fibrillation Complicated with Coronary Artery Disease: Interpretation of 2019 AHA/ACC/HRS Guidelines

Discussion

Antithrombotic Therapy in Patients with Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: Interpretation of the 2018 Updated North American Perspective

Discussion

Interpretation of 2018 EHRA Expert Consensus on Antithrombotic Treatment of Atrial Fibrillation with ACS/PCI

Discussion

Application of Dabigatran in Atrial Fibrillation

Dual vs. Triple Antithrombotic Therapy after PCI

Antithrombotic Therapy After PCI: From RE-DUAL PCI to Complex Clinical Cases

China's Voice in ESC: Exploring the Risk of Thrombosis and Bleeding in Patients with COVID-19

Discussion

Anticoagulant Selection in Patients with Atrial Fibrillation and Coronary Artery Disease

Discussion

Antiarrhythmic Drug Selection in Patients with Atrial Fibrillation and Coronary Artery Disease

Discussion

Individualized Antiplatelet Therapy in Patients with Coronary Artery Disease Treated with Oral Anticoagulants

Discussion

Selection of Antiplatelet Drugs in Patients with Atrial Fibrillation and Coronary Artery Disease

Discussion

Debate: LAA Closure is Recommended for Alternative to Anticoagulation in Patients with Atrial Fibrillation after PCI: Pros

Discussion

Debate: Dual Antithrombotic Therapy is the Standard Treatment in AF Patients Undergoing PCI: Pros

Discussion

Debate: Dual Antithrombotic Therapy is the Standard Treatment in AF Patients Undergoing PCI: Cons

Disscussion

Opening

Key Points of the Chinese Expert Consensus on Antithrombotic Management in Patients with Coronary Artery Disease and Atrial Fibrillation

Further Insights into the Chinese Expert Consensus on Antithrombotic Management in Patients with Coronary Artery Disease and Atrial Fibrillation

Exploration of Anticoagulation for Coronary Thrombosis: A Evidence-Based Analysis

Exploration of DPI for Coronary Thrombosis: A Mechanism Analysis

Antithrombotic Strategy for Chronic Coronary Syndrome Patients with Peripheral Artery Disease

Discussion

Advances in Antithrombotic Therapy: Insights from the ESC Guidelines on Management of Non-ST Elevation ACS

Discussion

Interpretation of Chinese Expert Consensus on Antithrombotic Management of Patients with Atrial Fibrillation and Coronary Artery Disease

Discussion

Antithrombotic Therapy in CAD Patients with COVID-19

Discussion

How to Reduce the Risk of Stent Thrombosis in Patients Treated with Bio-Resorbable Stent: Insights from the Chinese Expert Consensus on the Clinical Application of Coronary Bioresorbable Scaffold

Discussion

New Era of P2Y12 Inhibitor Monotherapy: Insights from the TWILIGHT Trial

Discussion

How Far Does Precise Antithrombotic Therapy Stay with Us: Insights from the TAILOR-PCI Trial

Discussion

The Double-Edged Sword of Antithrombotic Therapy on Diabetes: Insight from the THEMIS Trial

Discussion

Antithrombotic Therapy of Patients with Coronary Artery Disease and Atrial Fibrillation: Insight from the AUGUSTUS Trial

Discussion

Real-World Experiences on Perioperative Antithrombotic Therapy in Patients undergoing PCI: Lessons from the CCC Project

Discussion

Dual Antiplatelet Therapy after PCI: A Single-Center Data Analysis from Fuwai Hospital

Discussion

Current Status of Antiplatelet Therapy of CAD Patients in China: Insights from the OPT-CAD Study

Discussion

Parenteral Anticoagulation Therapy in Chinese Patients Undergoing PCI for ACS

Discussion

Antithrombotic Strategies for Medically Managed ACS Patients

Antithrombotic Strategies for Elderly CAD Patients

Antithrombotic Therapy for CAD Patients Complicated with Atrial Fibrillation

Application of NOAC in High Risk CAD Patients

Exploration on De-Escalation of Antiplatelet Therapy

Short DAPT Durations after New Generation DES Implantation

Antithrombotic Strategies for ACS Patients with High Bleeding Risk

Optimized Antithrombotic Therapy in ACS Patients undergoing PCI

Experience of Bivalirudin during Emergency PCI for STEMI

Optimal DAPT Duration in ACS Patients after PCI

Diagnosis and Management of Thrombocytopenia in ACS Patients undergoing PCI

Prevention and Management of GI Bleeding in ACS Patients on DAPT

Opening

Overview of Antithrombotic Therapy for Coronary Artery Disease

Development and Exploration of Antithrombotic Strategy After PCI

Optimized Antithrombotic Therapy in Patients with Chronic Coronary Artery Disease with High Ischemic Risk: Lessons from COMPASS Study

New Considerations of Precise Primary Prevention of Coronary Artery Disease

Risk Assessment and Management of Gastrointestinal Tract Damage Caused by Antiplatelet Drugs

Discussion